ACRV stock icon

Acrivon Therapeutics
ACRV

$7.25
6.09%
 

About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Employees: 61

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 11 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

46% more capital invested

Capital invested by funds: $74.4M [Q4 2023] → $109M (+$34.6M) [Q1 2024]

15% more funds holding

Funds holding: 41 [Q4 2023] → 47 (+6) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0.23% less ownership

Funds ownership: 68.93% [Q4 2023] → 68.7% (-0.23%) [Q1 2024]

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$14
93%
upside
Avg. target
$19.91
175%
upside
High target
$30
314%
upside

11 analyst ratings

11 positive
100%
neutral
0%
negative
0%
BMO Capital
Etzer Darout
245%upside
$25
Outperform
Reiterated
15 May 2024
HC Wainwright & Co.
Emily Bodnar
203%upside
$22
Buy
Maintained
14 May 2024
BMO Capital
Etzer Darout
245%upside
$25
Outperform
Maintained
26 Apr 2024
JMP Securities
Silvan Tuerkcan
134%upside
$17
Market Outperform
Maintained
25 Apr 2024
Piper Sandler
Joseph Catanzaro
314%upside
$30
Overweight
Maintained
25 Apr 2024

Financial journalist opinion

Based on 6 articles about ACRV published over the past 30 days